A Phase IIa, Double-blind, Randomized, Placebo-controlled Trial in Participants With Asthma to Evaluate the Impact of Intranasal ETH47 on the Development of Asthma-related Symptoms Following Rhinovirus Challenge
Latest Information Update: 24 Jul 2025
At a glance
- Drugs ETH-47 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors ethris
Most Recent Events
- 11 Jul 2025 Status changed from planning to recruiting.
- 30 Jan 2025 According to an Ethris GmbH media release,Based on the encouraging Phase 1 results, Ethris filed a Clinical Trial Application (CTA) for a Phase 2a rhinovirus challenge study in asthma patients, planned to begin in Q2 2025.
- 19 Jun 2024 New trial record